Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management (Q33438490)

26 July 2017

title

Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management (English)

1 reference

26 July 2017

1

Morie A Gertz

1 reference

26 July 2017

language of work or name

1 reference

1 February 2017

1 reference

American Journal of Hematology

26 July 2017

published in

1 reference

26 July 2017

volume

92

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

209-217

1 reference

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

26 July 2017

cites work

1 reference

Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: A two-institution study

21 January 2018

1 reference

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

21 January 2018

1 reference

Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.

21 January 2018

1 reference

Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival

21 January 2018

1 reference

Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients

21 January 2018

1 reference

Outcome disparities among ethnic subgroups of Waldenström's macroglobulinemia: a population-based study

21 January 2018

1 reference

Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia

21 January 2018

1 reference

Neurological manifestations of Waldenström macroglobulinemia

21 January 2018

1 reference

Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia

21 January 2018

1 reference

Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.

21 January 2018

1 reference

Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.

21 January 2018

1 reference

Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis

21 January 2018

1 reference

Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.

21 January 2018

1 reference

IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia

21 January 2018

1 reference

Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study

21 January 2018

1 reference

Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia

21 January 2018

1 reference

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

21 January 2018

1 reference

First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis.

21 January 2018

1 reference

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

21 January 2018

1 reference

How I treat Waldenström macroglobulinemia

21 January 2018

1 reference

Autoantibody activity in Waldenstrom's macroglobulinemia

21 January 2018

1 reference

IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia

21 January 2018

1 reference

Prevalence, clinical aspects, and natural history of IgM MGUS.

21 January 2018

1 reference

Pathogenesis and progression of monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia

21 January 2018

1 reference

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

21 January 2018

1 reference

Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification

21 January 2018

1 reference

Prognostic factors in follicular lymphoma.

21 January 2018

1 reference

International prognostic scoring system for Waldenstrom macroglobulinemia

21 January 2018

1 reference

Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.

21 January 2018

1 reference

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia

21 January 2018

1 reference

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

21 January 2018

1 reference

Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase

21 January 2018

1 reference

The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

21 January 2018

1 reference

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

21 January 2018

1 reference

Risk of second cancers in Waldenström macroglobulinemia

21 January 2018

1 reference

Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.

21 January 2018

1 reference

21 January 2018

Hyperviscosity syndrome.

1 reference

Evidence-based focused review of management of hyperviscosity syndrome

21 January 2018

1 reference

Role of plasmapheresis in Waldenström's macroglobulinemia

21 January 2018

1 reference

Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome.

21 January 2018

1 reference

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

21 January 2018

1 reference

Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).

21 January 2018

1 reference

Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials.

21 January 2018

1 reference

Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil

21 January 2018

1 reference

Monoclonal gammopathy and neuropathy.

21 January 2018

1 reference

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

21 January 2018

1 reference

Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.

21 January 2018

1 reference

Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma

21 January 2018

1 reference

Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003)

21 January 2018

1 reference

Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.

21 January 2018

1 reference

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

21 January 2018

1 reference

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

21 January 2018

1 reference

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

21 January 2018

1 reference

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Stu

21 January 2018

1 reference

High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 cases

21 January 2018

1 reference

Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique

21 January 2018

1 reference

Autologous Stem Cell Transplantation as a Care Option in Waldenström's Macroglobulinemia

21 January 2018

1 reference

Hematopoietic cell transplantation for Waldenström macroglobulinemia.

21 January 2018

1 reference

Thalidomide and rituximab in Waldenstrom macroglobulinemia

21 January 2018

1 reference

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

21 January 2018

1 reference

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

21 January 2018

1 reference

Bortezomib in relapsed or refractory Waldenström's macroglobulinemia

21 January 2018

1 reference

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

21 January 2018

1 reference

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

21 January 2018

1 reference

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

21 January 2018

1 reference

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

21 January 2018

1 reference

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

21 January 2018

1 reference

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

21 January 2018

1 reference

Novel treatment regimens for Waldenström's macroglobulinemia

21 January 2018

1 reference

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

21 January 2018

1 reference

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

21 January 2018

1 reference

Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.

21 January 2018

1 reference

Ibrutinib in previously treated Waldenström's macroglobulinemia.

21 January 2018

1 reference

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines

21 January 2018

1 reference

Multiple myeloma, version 1.2013.

21 January 2018

1 reference

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

21 January 2018

1 reference

Waldenström's macroglobulinemia

21 January 2018

1 reference

Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide

21 January 2018

1 reference

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.24557

1 reference

26 July 2017

1 reference